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DISCUSSION
Audience (unidentified speaker). Just one question. Why
did you pick age 60 as a definition for premature atherosclerosis? I
think in Valentine’s work it is age 50, and I know other authors
who have actually called it age 40, so it seems like the definition of
premature keeps getting older and older. Any answers about why
you did that?
Dr John Lane. Thank you for the question. Yes, as you are
familiar with the literature, Dr Valentine’s group actually a lot of
times would define this as age 45. One of the reasons we defined it
as age 60 is that some authors have used this in the past. It is kind
of a moving target of how and when you define premature periph-
eral vascular disease, and one of the reasons I did allow for a
roughly equal sample size in both the older and younger age
groups. We did look at different cut points, and it didn’t really
significantly change our findings by using a cutoff at age 45.
Dr Charles Andersen (Tacoma, Wash). I rise to suggest that
it may be time for a terminology change in our field. We talk about
peripheral vascular disease as if it were something separate, a
separate area of atherosclerosis. I would throw out a suggestion
that screening with ABIs is not about the legs at all. It is about early
detection of atherosclerotic vascular disease and then an aggressive
approach to a systemic disease. My question is if you pick up an
early abnormal ABI, what do you do from there?
Dr Lane. Thank you for the question and your observation. I
do think this is incredibly important. In fact, there was a recent
article in theAnnals of InternalMedicine out ofUCSF that showed
now ABI screening is also important in predicting early renal
failure, so it seems that ABIs are becoming an incredibly powerful
marker, and you are right, it is not just for detecting peripheral
vascular disease, but finding for vascular disease in the entire body.
To your question, I think when you find a patient with an
abnormal ABI, this is your opportunity to afford early secondary
intervention. How this can be done is by altering risk factors,
including the treatment of hypertension, cholesterol, and diabetes,
and the new serologic risk factors that we were analyzing in the
study. I think we also have some evidence that there is medical
treatment for them. So I think this is a way that we can prevent
patients from coming to the operating table and trying to treat
these risk factors early when you identify them with an early
abnormal ABI.
Audience (unidentified speaker). Very nice presentation. If
you ask a practicing vascular surgeon what the greatest risk factors
are for the younger patients, it seems to me the no-brainers would
be patients who have type 1 or insulin-dependent diabetes and
patients on dialysis, chronic renal failure. I may have missed it in
your methodology, but were those patients excluded, or could you
explain how the data would be assessed that those patients would
not fall out in your analysis, because to me, those are the no-
brainers. These are the subtle risk factors that we don’t always
measure, but I would think that the highest risk would be in that
group of patients, and that is what our clinical experience is.
Dr Lane. Thank you. Yes, diabetes and dialysis are certainly
very important risk factors. Diabetes was included; however, we
did not—the data in NHANES was not stratified to type 1 versus
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type 2 diabetes—so, unfortunately, I can’t give you which type of
diabetes. Dialysis patients were not excluded from sampling in
NHANES. I did not present nor did I analyze the dialysis group
independently. One of the reasons was because even with the
sampling, there were 5000 patients in the sample. The occurrence
was only 2% in the younger age category and 12% in the older. If
you start breaking it down all the way to the number actually on
dialysis, the number of outcomes is going to be small in the age
category, and it might not have been powerful in the analysis so
that wasn’t performed, but, yes, we all know that is incredibly
important in developing premature disease.
Dr Christian Devirgilio (Los Angeles, Calif). I enjoyed your
presentation. Very nice work. I had sort of a practical question for
the family practitioner who might be looking to screen. Given that
hypertension and smoking were important risk factors in both old
and young, if they were to simply use smoking and hypertension as
a guide to getting the simple ABI, how many patients would be
missed if you did not use, say, the fibrinogen? In other words, is it
practical to be telling the family practitioner that they should be
screening fibrinogen when a simple ABI could be done just based
on smoking and hypertension?
Dr Lane. Thank you, Dr Devirgilio. Yes, very insightful.
When you are talking about screening a general population, cer-
tainly the strongest risk factors are the ones that aremost important
such as smoking and hypertension as well as diabetes. Whether
these serologic risk factors are really important in the general
population, it may not be clear, and certainly our data do not bear
that out. When you are talking about screening for those things, I
think it is more important in a high-risk population. There was a
paper out of The Cleveland Clinic that looked at screening for
these more subtle risk factors in patients that are extremely high
risk, such as referrals to a high-risk cardiology clinic, and in our
instance, maybe a referral to a vascular clinic. In those, the novel
risk factors did add something to the prediction, and again, it offers
an opportunity for treatment. So in a general population such as a
US population, which I am talking about here, I don’t think our
data support that this makes sense. I think you should concentrate
on the big risk factors such as smoking, hypertension, and diabetes,
but when you are looking at a referral population or a high-risk
population, I think in that case it makes sense and I think this
should be considered more closely in our peripheral vascular
patients in a future study.
Dr Thomas Rehring (Denver, Colo). I have one comment
and then a question for you. To Dr Andersen’s question, I mean
those patients who you identify with a diagnosis of PAD should
instantly be started on all secondary prevention strategies you
initiate in somebody with coronary artery disease, which would
include -blockade, ACE inhibitors, antiplatelet therapy, and
probably a statin to target an LDL of less than 100. I think it is
within our purview and should be our recommendation, if we
don’t initiate therapy ourselves, that you should have a strong
letter back to that referring physician.
My question for you is this: we know that as many as two thirds
of patients in the elderly population that have a diagnosis of
peripheral arterial disease would be asymptomatic, that is, they can
be identified with a low ABI but may not have symptoms. It is my
impression that the younger population presents more commonly
with symptoms. Did they have data from this survey at all about
how many of these patients had symptoms?
Dr Lane. Yes. Thank you for your question. I certainly agree
with aggressive medical therapy for all people that have evidence of
vascular disease in any of the peripheral or coronary beds.
The lower extremity examination did have a symptom index,
or at least they ask if people are having claudication. Again, it
wasn’t very detailed and again, when you are talking about younger
patients with symptoms, when you are getting down to that small
of numbers, the analysis is not very powerful, so I did not include
that in the analysis; but, yes, the NHANES data set in the lower
extremity does ask if you have leg pain with walking and that is
something that could be analyzed in a future study.
Dr Preston Flanagin (Orange, Calif). Regarding the ankle-
brachial index being the best way to screen for peripheral vascular
disease in terms of having early intervention, I think that it is
actually a late manifestation if your ankle-brachial index is abnor-
mal. Most active patients that have an abnormal ankle-brachial
index are going to be symptomatic. If you have an abnormal
ankle-brachial index, you already have a critical stenosis somewhere
in your lower extremity vasculature. I have always been intrigued
with the use of that and I suspect it is mostly for cost reasons, but
it seems to me that duplex scanning, as we do for the carotids and
as we do for screening for abdominal aortic aneurysms, would be a
lot more effective in finding earlier peripheral vascular disease and
therefore allow for earlier and hopefully more effective interven-
tion.
Dr Lane. Thank you for your comment. We did use a very
somewhat high cut point. Most of us would not consider treating
a patient with an ABI of 0.9 unless they are very symptomatic from
that, which is hard to imagine, but certainly when you are talking
about ABIs in the lower category certainly they do also—say if you
use a cutoff of 0.5—they all have very profound peripheral and
possibly atherosclerotic disease in other vascular beds. Certainly,
this study does not look at duplex scanning as a sensitive marker.
People have tried to do this looking in the carotid circulation and
measuring intimal-to-medial thickness as trying to be an early
marker. Certainly, that is something important. People have tried
to use this as a predictive tool; however, we did not use this in the
study, and I don’t have any data to present that for the group.
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